Regular or Decaf? Options for Quantitative Biomarker Discovery Mary F Lopez Director, BRIMS MSACL San Diego, Feb 8, 2011.
Serendipity in the Blood: Mass spectrometry in the discovery of clinical biomarkers AFMR Symposium Boston, 4/24/13 Mary F Lopez, Director BRIMS Biomarker.
Conclusion
Advantages of a Two-Pass Workflow for Biomarker Discovery in Plasma or Serum Samples for Clinical Research Maryann S Vogelsang 1, Bryan Krastins 1, David.
Serendipity in the Blood: Mass spectrometry in the discovery of clinical biomarkers
